TW202334170A - 造血前驅細胞激酶之雙官能降解劑及其治療用途 - Google Patents

造血前驅細胞激酶之雙官能降解劑及其治療用途 Download PDF

Info

Publication number
TW202334170A
TW202334170A TW111142873A TW111142873A TW202334170A TW 202334170 A TW202334170 A TW 202334170A TW 111142873 A TW111142873 A TW 111142873A TW 111142873 A TW111142873 A TW 111142873A TW 202334170 A TW202334170 A TW 202334170A
Authority
TW
Taiwan
Prior art keywords
group
alkyl
compound
substituted
halogen
Prior art date
Application number
TW111142873A
Other languages
English (en)
Chinese (zh)
Inventor
約翰 布埃爾
佛萊德瑞克 柯恩
萊恩 潘柏頓
杭特 P 夏納多納
嵐 王
馬克 愛德華 札克
Original Assignee
美商新銳思生物製藥股份有限公司
美商基利科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商新銳思生物製藥股份有限公司, 美商基利科學股份有限公司 filed Critical 美商新銳思生物製藥股份有限公司
Publication of TW202334170A publication Critical patent/TW202334170A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
TW111142873A 2021-11-10 2022-11-09 造血前驅細胞激酶之雙官能降解劑及其治療用途 TW202334170A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163263875P 2021-11-10 2021-11-10
US63/263,875 2021-11-10

Publications (1)

Publication Number Publication Date
TW202334170A true TW202334170A (zh) 2023-09-01

Family

ID=85132852

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142873A TW202334170A (zh) 2021-11-10 2022-11-09 造血前驅細胞激酶之雙官能降解劑及其治療用途

Country Status (12)

Country Link
US (2) US12091426B2 (https=)
EP (1) EP4430052A1 (https=)
JP (1) JP2024543377A (https=)
KR (1) KR20240101654A (https=)
CN (1) CN118510786A (https=)
AR (1) AR127625A1 (https=)
AU (1) AU2022388571A1 (https=)
CA (1) CA3235913A1 (https=)
IL (1) IL312361A (https=)
MX (1) MX2024005431A (https=)
TW (1) TW202334170A (https=)
WO (1) WO2023086399A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2025029995A1 (en) * 2023-08-01 2025-02-06 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof
CN117126133A (zh) * 2023-08-14 2023-11-28 中国海洋大学 一种化合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600373YA (en) 2013-07-31 2016-02-26 Gilead Sciences Inc Syk inhibitors
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
JP7472103B2 (ja) 2018-08-22 2024-04-22 クルゲン(シャンハイ),インク. トロポミオシン受容体キナーゼ(trk)分解化合物とその使用方法
WO2020092528A1 (en) * 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
JP7503851B2 (ja) 2019-05-06 2024-06-21 アイカーン スクール オブ メディスン アット マウント シナイ Hpk1の分解剤としてのヘテロ二官能性化合物
WO2021168197A1 (en) 2020-02-19 2021-08-26 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
US11739101B2 (en) * 2020-05-06 2023-08-29 Nurix Therapeutics, Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Also Published As

Publication number Publication date
JP2024543377A (ja) 2024-11-21
KR20240101654A (ko) 2024-07-02
CN118510786A (zh) 2024-08-16
WO2023086399A1 (en) 2023-05-19
IL312361A (en) 2024-06-01
US20240018162A1 (en) 2024-01-18
MX2024005431A (es) 2024-07-19
AU2022388571A1 (en) 2024-05-09
CA3235913A1 (en) 2023-05-19
US12091426B2 (en) 2024-09-17
US20240400587A1 (en) 2024-12-05
AR127625A1 (es) 2024-02-14
EP4430052A1 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
JP6942896B2 (ja) Parp7阻害剤としてのピリダジノン
US11739101B2 (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
TWI886406B (zh) 介白素-1受體相關激酶之雙官能降解劑及其治療用途
TW202334170A (zh) 造血前驅細胞激酶之雙官能降解劑及其治療用途
TW201938555A (zh) Kras g12c抑制劑
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
AU2022297176A1 (en) Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof
TW202400580A (zh) 作為配體導向降解劑之bcl6調節劑
TWI918648B (zh) 造血前驅細胞激酶之雙官能降解劑及其治療用途
HK40115438A (zh) 造血祖细胞激酶的双功能降解剂及其治疗用途
CN120957981A (zh) 基于2,4-二苯胺嘧啶的Aurora-A激酶选择性降解诱导化合物
CN115557946A (zh) 杂环内酰胺类化合物,包含其的药物组合物及其用途
WO2025096771A1 (en) Modulators of bcl6 as ligand directed degraders
CN117396477A (zh) 用于治疗癌症的经吡啶基取代的氧代异吲哚啉化合物
OA21863A (en) Indazole based compounds and associated methods of use.